Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer, Metastatic
Interventions: DRUG: BAY59-8862 (Cytotoxic Taxane)
Sponsor: Bayer